The DOI matches its Crossref record; 140 of the 140 references it cites were found in a registry or an index.
Adeno-Associated Virus (AAV) - Based Gene Therapies for Retinal Diseases: Where are We?
Open accessAbstract
Owing to their small size and safety profiles, adeno-associated viruses (AAVs) have become the vector of choice for gene therapy applications in the retina. In addition to the naturally occurring AAVs, several engineered variants with enhanced properties are being developed for experimental and therapeutic applications. Nonetheless, there are still some challenges impeding successful application of AAVs for a broader range of retinal gene therapies. The small size of AAV particles ensures efficient tissue transduction but also limits the packaging capacity to a few kilobases. Further, AAV's ability to cross retinal barriers is still an obstacle to pan-retinal transduction of the outer retina with tolerable doses. Lastly, despite overall safety, there have been recent reports of immune responses to AAVs in the eye. Hence, evaluation and prediction of immune responses to AAVs has come to be considered an integral part of future clinical success. This review focuses on the use of AAV in clinical trials for retinal diseases, and discusses developments of variants and novel strategies to overcome immune responses to AAVs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“A significant barrier to effective intraocular rAAV gene delivery is the interaction of the vector with the host’s immune system [5].”
From Characterization of anti-AAV2 neutralizing antibody levels in sheep prior to and following intravitreal AAV2.7m8 injection (2024) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wong, W. L., Su, X., Li, X., Cheung, C. M. G., Klein, R., Cheng, C.-Y., & Wong, T. Y. (2014) · The Lancet Global Health · doi:10.1016/s2214-109x(13)70145-1 · Cited by 5,331
Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage
Gaudelli, N. M., Komor, A. C., Rees, H. A., Packer, M. S., Badran, A. H., Bryson, D. I., & Liu, D. R. (2017) · Nature · doi:10.1038/nature24644 · Cited by 4,184 · cited 2×
“BEs are DNA editing tools that use a dead Cas9 (dCas9; no/residual catalytic activity) fused with cytidine (CBEs) or adenine (ABEs) deaminases allowing single base conversion of C:G>T:A or A:T> G:C.(27,58) This strategy is particularly relevant in both monogenic autosomal recessive and autosomal dominant diseases cont…”
BackgroundNon-viral vectors for gene-based therapy
Yin, H., Kanasty, R. L., Eltoukhy, A. A., Vegas, A. J., Dorkin, J. R., & Anderson, D. G. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3763 · Cited by 3,123 · cited 1×
“Non-viral vectors are a heterogenous family including various components such as lipid nanoparticles (LNPs), polymer-based vectors, or inorganic materials.(75,76) Nonetheless, when it comes to the retina, those vectors, which are bigger (~100–200nm) than AAVs (~25nm), may face numerous physical and physiological barri…”
BackgroundIn vivo genome editing using Staphylococcus aureus Cas9
Ran, F. A., Cong, L., Yan, W. X., Scott, D. A., Gootenberg, J. S., Kriz, A. J., Zetsche, B., Shalem, O., Wu, X., Makarova, K. S., et al. (2015) · Nature · doi:10.1038/nature14299 · Cited by 2,687
Genome editing with CRISPR–Cas nucleases, base editors, transposases and prime editors
Anzalone, A. V., Koblan, L. W., & Liu, D. R. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0561-9 · Cited by 2,237
Effect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924 · cited 1×
“However, long-term follow-up in 2 out of 3 clinical trials reported a decline in the visual gains in adult patients, indicating that the treatment was unable to halt the degeneration.(15,19) This highlights two important aspects: the level of AAV transduction required for therapeutic benefits in humans may be higher a…”
BackgroundCRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
Gillmore, J. D., Gane, E., Taubel, J., Kao, J., Fontana, M., Maitland, M. L., Seitzer, J., O’Connell, D., Walsh, K. R., Wood, K., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107454 · Cited by 1,801
Viral vector platforms within the gene therapy landscape
Bulcha, J. T., Wang, Y., Ma, H., Tai, P. W. L., & Gao, G. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00487-6 · Cited by 1,404
Gene therapy restores vision in a canine model of childhood blindness
Acland, G. M., Aguirre, G. D., Ray, J., Zhang, Q., Aleman, T. S., Cideciyan, A. V., Pearce-Kelling, S. E., Anand, V., Zeng, Y., Maguire, A. M., et al. (2001) · Nature Genetics · doi:10.1038/ng0501-92 · Cited by 1,202 · cited 1×
“The proof-of-concept for vision restoration was provided in a canine model.(14) This led to clinical trials involving LCA2 patients who received SR injections of RPE65 packaged in AAV2 via SR delivery.”
BackgroundBoutin, S., Monteilhet, V., Veron, P., Leborgne, C., Benveniste, O., Montus, M. F., & Masurier, C. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.182 · Cited by 970
Cited by
Nucleic acid-based drugs for patients with solid tumours
Huayamares, S. G., Loughrey, D., Kim, H., Dahlman, J. E., & Sorscher, E. J. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00883-1 · Cited by 61
Agrahari, V., Choonara, Y. E., Mosharraf, M., Patel, S. K., & Zhang, F. (2024) · Pharmaceutical Research · doi:10.1007/s11095-024-03798-9 · Cited by 61
Combined AAV-mediated specific Gjb2 expression restores hearing in DFNB1 mouse models
Sun, Q., Tan, F., Zhang, L., Lu, Y., Hao, W., Li, N., Jiang, L., Zhou, Y., Chen, T., Ling, L., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.029 · Cited by 43
An adeno-associated virus variant enabling efficient ocular-directed gene delivery across species
Luo, S., Jiang, H., Li, Q., Qin, Y., Yang, S., Li, J., Xu, L., Gou, Y., Zhang, Y., Liu, F., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-48221-4 · Cited by 39
“A goodcapsid variant possesses immensecommercialvalue and holds promising prospects for application 13,51 .”
Breaking genetic shackles: The advance of base editing in genetic disorder treatment
Xu, F., Zheng, C., Xu, W., Zhang, S., Liu, S., Chen, X., & Yao, K. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1364135 · Cited by 34
Metadata
- Authors
- Ail, D., Malki, H., Zin, E. A., & Dalkara, D.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- Corresponding author
- Ail, Divya
- Malki, Hugo
- Zin, Emilia A
- Dalkara, Deniz
- Venue
- The Application of Clinical Genetics
- Publisher
- Informa UK Limited
- Published
- 2023-05
- Volume
- Volume 16
- Pages
- 111-130
- ISSN
- 1178-704X (ISSN-L)
- PMC
- PMC10239239
- OpenAlex
- W4379377001
- Cited by
- 40
- References
- 139
- Citations by year
- 2026: 7 · 2025: 13 · 2024: 17 · 2023: 3
- FWCI
- 1.54
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- The Application of Clinical Genetics (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- adeno-associated virus, retinal gene therapy, adeno-associated virus vectors, retinal transduction, outer retina, retinal disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Adeno-Associated Virus (AAV) - Based Gene Therapies for Retinal Diseases: Where are We? https://app.cochat.ai/papers/10.2147/tacg.s383453
- The paper
- Ail, D., Malki, H., Zin, E. A., & Dalkara, D. (2023). Adeno-Associated Virus (AAV) - Based Gene Therapies for Retinal Diseases: Where are We? The Application of Clinical Genetics. https://doi.org/10.2147/tacg.s383453
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.